04/16/2026
🚨Big update in the peptide space. 💉
Today marks a shift toward science, accountability, and transparency.
In September 2023, the FDA placed multiple peptides into Category 2 — labeling them as substances that raise significant safety concerns. The result? Limited access and a growing black market that ultimately put patients at risk.
Now, that’s changing.
After nominators withdrew support for 12 peptides, the FDA has announced they will be removed from Category 2 and sent to the PCAC (Pharmacy Compounding Advisory Committee) for formal review starting in July.
This means these substances will now be evaluated the right way —
✔️ Clinical data
✔️ Pharmacology
✔️ Safety evidence
✔️ Independent expert review
The 12 peptides include:
• BPC-157
• Thymosin beta-4 fragment (LKKTETQ)
• Epitalon
• GHK-Cu (injectable)
• MOTS-c
• DSIP (Emideltide)
• Dihexa Acetate
• Ibutamoren Mesylate
• Melanotan II
• KPV
• Semax (heptapeptide)
• Cathelicidin LL-37
At SoWal Pharmacy, we believe in evidence-based care, transparency, and patient safety — not driving people toward unsafe alternatives.
We’ll continue to follow this closely and keep you updated as the science evolves.
💊 Questions about peptides or compounding? We’re here to help.
📍 SoWal Pharmacy – Miramar Beach
🌐 SOWALRXPHARMACY.com
PatientSafety FunctionalMedicine Wellness EvidenceBased PharmacyLife